David Brinton

Cooley advised Aclaris Therapeutics (Nasdaq: ACRS), a clinical-stage biopharmaceutical company developing novel drug candidates for immuno-inflammatory diseases, on its exclusive license agreement with Biosion and $80 million private placement.

The Chapter 11 plan of PhaseBio Pharmaceuticals, a long-standing Cooley life sciences client, has gone effective following the court’s confirmation of the Chapter 11 plan on June 26, 2024. The plan provides for a global settlement with the official committee of unsecured creditors and a settlement with PhaseBio’s former co-development partner. The Chapter 11 bankruptcy case in the US Bankruptcy Court for the District of Delaware was handled by a multioffice, cross-disciplinary Cooley team.

Cooley advised Impact Analytics, a provider of the industry’s most innovative retail, grocery, consumer packaged goods, and supply chain-focused planning and merchandising software suite, on the close of its $40 million growth financing.

Cooley advised MapLight Therapeutics, a clinical-stage biopharmaceutical company, on its oversubscribed $225 million Series C financing.

Cooley advised Instil Bio on its $368 million initial public offering of 18,400,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Instil Bio, whose securities now trade on the Nasdaq Global Market under the symbol TIL, is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocytes therapies for the treatment of patients with cancer. Partners Div Gupta, Madison Jones and Brent Siler led the Cooley team.